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In 1984, while tracking the veins of
globin gene evolution and panning the
human genome for hypervariable linkage
markers, Sir Alec Jeffreys accidentally
struck gold—he discovered a way to
identify any human being by a DNA
‘‘fingerprint’’. To use Jeffreys’ words, he
has been ‘‘branded’’ by DNA fingerprint-
ing, but he delights in its application and
the hook it provides for public curiosity
about science. Like Jeffreys himself, I
wanted to dig below the surface of this
discovery as well as that of another genetic
nugget—the intervening sequence—found
as a post-doctoral fellow seven years
earlier.
On the heels of my interview with
Adrian Bird (published in the October
issue of PLoS Genetics), I made my way to
Jeffreys through another branch of the
British Rail system. When I arrived at his
building on the leafy Leicester campus
about 45 minutes early for our appoint-
ment, his assistant suggested I get a cup of
coffee while Jeffreys finished his experi-
ment. I certainly wouldn’t have needed
one. Jeffreys (Image 1) is an animated
speaker, with a resonant voice and a rapid
delivery of succinct clauses strung together
in run-on sentences. His story could have
cut through anyone’s jet lag.
Gitschier: I didn’t realize that you still
work in the laboratory.
Jeffreys: I certainly do!
Gitschier: Tell me about the experi-
ment you were just doing.
Jeffreys: Right, well, we won’t go into
the gory details. Copy number variation
[CNV] in the human genome is a real hot
topic at the moment.
Gitschier: The kind of variations
people are looking for in association with
autism and psychiatric diseases.
Jeffreys: That’s exactly right. It’s a
common phenomenon, and we’ve actu-
ally known that for decades. What we’re
doing is going back to some of the
absolutely classic examples of CNV.
These are in my favorite gene family—
the globin genes—and that’s where I cut
my scientific teeth.
Gitschier: We’re going to be coming
back to that!
Jeffreys: Right. So, what I’ve done in
my scientific career is this gigantic circle,
starting off in globin genes, going all
around the place in forensics, and return-
ing back to my first love. The experiment
I’m doing at the moment is looking at de
novo copy number variation in the fetal c-
globin genes at the single molecule level in
both somatic and germline DNA.
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recombination hotspots. And the general
feeling was that recombination hotspots
function at meiosis—they drive allelic
recombination, and they may well drive
ectopic recombination.
Gitschier: Define ‘‘ectopic.’’
Jeffreys: The term ectopic originally
came from yeast and it applied there to a
situation in which you have a sequence
repeated, say here and there, so that they
can undergo unequal crossover and cause
duplication and deletion. ‘‘Ectopic’’ re-
combination means it’s ‘‘out of place.’’
As of yesterday, I found there is copy
number instability not just in the germline,
but in somatic DNA. That largely rules
out meiosis and meiotic recombination
hotspots. Even in the germline it is quite
clear that the substantial proportion,
possibly the great majority of rearrange-
ments, are again pre-meiotic, arising
during germ cell development. We’re
trying to drill down below the applied
genetics [looking for variation associated
with disease], to some of the fundamental
mechanisms, to understand the dynamics
of rearrangements in the human genome.
So, if you want to put a simple summary
on what this lab is about, it’s about human
DNA diversity and the processes that
generate it.
Gitschier: OK! Now let’s get to the
first question on my list, which indeed is
about globin. It’s about the period of your
post-doc in Amsterdam. Why did you go
there and why work with Flavell?
Jeffreys: OK. I did my D. Phil. at
Oxford University on human somatic cell
genetics. Then went to a Biochemical
Society meeting and chatted with a chap
named Piet Borst, a very senior scientist,
who at the end said, if you are interested in
doing a post-doc with me, just let me
know.
And I thought, that’s great, 9cause I
wanted to get out of Oxford, and Holland I
really fancied because the language wasn’t
going to be a problem; everyone speaks
English. So, I got myself an EMBO fellow-
ship to work with Piet on yeast tRNA genes.
In 1975, the door was clearly opening
on molecular genetics, before that, it
wasn’t worth talking about.
Gitschier: Expand on that statement.
Jeffreys: I remember very clearly.
There was a colleague of mine at Oxford
called David Finnegan and we’re waiting
in the lunch queue and he wanted to go off
to the States, and I said what’s the project,
and he said the idea is to take Drosophila
DNA and to try to stick bits of that into
lambda phage.
Gitschier: With David Hogness?
Jeffreys: Right. And the penny
dropped then, that this was going to be
the way forward.
I get to Amsterdam, and Piet said, you
c a nw o r ko nt h i si fy o ul i k e ,b u ty o um i g h t
also like to have a chat with this guy Dick
Flavell, he’s got a collaboration with
Charlie Weissman in Zurich, on trying
to isolate a mammalian gene. And I
thought—whoa! That’s sounds really
exciting. The idea of the project was to
get to a single-copy gene. No one had ever
done that in a mammalian system. The
only one we could possibly do, we felt,
was either rabbit a-o rr a b b i tb-globin,
because the mRNA had been purified.
T h eg e n ei s o l a t i o nw o u l db eb yp h y s i c a l
purification.
Gitschier: No cloning?
Jeffreys: Well, cloning came in right at
the end. It simply wasn’t around at the
time. It was by hybridization enrichment
with prodigious quantities of DNA [from
rabbit liver]. The experiment was to cut it
up with EcoRI restriction enzyme. Re-
member, this is back in the days when you
couldn’t just buy enzymes off the shelf, you
had to make them.
Then denature the DNA and hybridize it
to globin mRNA. This was a two-pronged
attack. In Amsterdam we were going to use
the mRNA to pull out the complementary
strand, heavily enriched, and in Zurich,
Charlie Weissman had managed to make a
cDNA so he could pull out the other strand,
and the idea was to purify our complemen-
tary strands and then meet somewhere in the
middle to hybridize the two stands back
together. Then, because this was an EcoRI
fragment, we could then pop it into a vector
that we hoped someone was about to
develop.
Gitschier: How were you selecting the
mRNA?
Jeffreys: We were selecting by attach-
ing mercury to the RNA and then
capturing it on a thiol column.
Gitschier: That’s a dangerous
experiment.
Jeffreys: Oh, the whole thing was
horrendous. We were using radioactive
mercury.
Gitschier: But hold on. Since there
was no reason to suspect that there were
intervening sequences, what is the point of
going after the gene?
Jeffreys: Nobody had ever seen a
mammalian gene. No one had any idea
of what it would look like.
Gitschier: So, the idea was to get
something bigger than the mRNA itself.
Jeffreys: Yes, that’s right. To look at
the flanking regions. Basic academic
curiosity.
During that experiment, we had to
develop methods for monitoring purifica-
tion, and the only way we could see to do
that was to use Ed Southern’s blotting
technique, which at that point was only a
year or two old.
So, as we purified the DNA we could
monitor the fractions just by running them
out on an agarose gel, doing the Southern
blot and then hybridizing with an appro-
priate complementary probe. And that not
only worked, but we could actually see the
fragment of DNA we were trying to purify
in the starting EcoRI digest of genomic
DNA.
Gitschier: Hadn’t he shown that
before?
Jeffreys: No, Ed was desperately
trying to get this going. I know Ed
extremely well, and there was a bit of
discomfort on my part thinking that we
had trampled on his patch. On the other
hand, that is what we needed to do.
Having got the ability to detect down to
the single gene level, we thought we should
see if we could make a restriction map
around the gene, which is what we did.
Gitschier: Were there EcoRI sites in
the cDNA?
Jeffreys: No. The cDNA had been
cloned by Tom Maniatis, and we pretty
quickly moved over to using his rabbit b-
globin cDNA that he very generously
provided to act as a probe for monitoring.
We just wanted to check that everything
was OK. And we built up a restriction
map around it [on genomic DNA via
Southern blotting].
We then discovered that there was an
EcoRI site right smack bang in the middle
of the gene! [That meant] our enrichment
experiment was a total disaster, because
we would have purified one end of the
gene in Amsterdam, and in Zurich, they
would have purified the other end of the
gene, and to put them together, there
would be nothing. The flop of the
millennium that was!
But, the question then was, what the
hell is the EcoRI site doing in the middle
of the gene? And then we started to do
more and more fine-mapping and it was
clear there was a huge gap in the gene.
I remember sitting down with my Dutch
technician, saying we’ve got the restriction
mapping data, let’s try putting all this
together. And I knew it was just nuts, but I
thought we could solve it if we just put an
extra dollop of DNA inside the gene. All of
this was done without reference to Phil
Sharp and Rich Roberts’s work with
adeno [which was happening at the same
time]. I knew instinctively that this was
something pretty exciting. And then, Dick
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Harbor Meeting, and everything started
falling together. About the same time, Phil
Leder managed to clone in lambda the
mouse b-globin gene and showed by
electron microscope analysis that there
was additional sequence inside the gene.
But the trouble there was it had been
cloned in E. coli and perhaps it was an
insertion sequence. And then [there was]
Chambon’s ovalbumin gene story.
Looking back on it, basically in 1977,
introns were going to be discovered. Full
stop. The technology had arrived to the
point where the discovery was inevitable. I
think all of us in the field were grateful that
we just happened to be at the right place at
the right time.
When it was time to leave Amsterdam,
one possibility was to do a post-doc with
Ed Southern up in Edinburgh. He’s a
great guy and the stuff he was doing was
fantastic. He’s one of my heroes. We are
actually quite similar. We like fiddling
around with things. He gave this wonder-
ful quote a few years ago that he misses the
days when he could get at the data before
the computer did.
But at the same time, I thought I’d like to
try running my own lab, and out of the blue
came a phone call from this guy called Bob
Pritchard who founded this Department [of
Genetics] in the early 60s. He said, ‘‘Would
you be interesting in coming for an inter-
view?’’ I said, ‘‘Where is it?’’ He said,
‘‘Leicester.’’ And I said, ‘‘That will be fine.’’
I put the phone down and I said,
‘‘Where the hell is Leicester?’’ All these
Dutch people were running around trying
to find a map of Europe.
Gitschier: Pre-internet.
Jeffreys: Pre-everything! These were
the days if you wanted a sequence you had
to get out a typewriter and type it in.
So, I visited Leicester and I immediately
fell in love with the department. I came as
a temporary lecturer, and I’m still here 32
years later, so it says something about the
environment. I love it here.
So, the question then was, what was I
going to do? It was clear that carrying on
with the intron work was not going to be
viable. Suddenly everybody was moving
into the field—evolution of introns, mech-
anisms of splicing, etc. I thought, take your
education in human genetics and your
new-fangled molecular biology and stick
them together. If you can pick up specific
bits of human DNA, then you should be
able to scan for variation. Variation that
affects a restriction enzyme site will
manifest as what is now called, I think
very uglily, an RFLP [restriction fragment
length polymorphism].
So, that was our first quest. By early
1978 we had picked up our first RFLP, a
rare variant in a single individual. Again,
these were in the globin gene clusters,
because again, these were the only genes
for which probes existed at that time.
Really excited, but we got pipped to the
post because Kan and Dozy published
their RFLP and the association with sickle
cell disease.
Gitschier: I think they just bumped
into that discovery.
Jeffreys: What we had done was to do
a fairly systematic survey for RFLPs in the
b-gene cluster.
Gitschier: What made you think that
there would be variation in restriction sites
among people?
Jeffreys: I can’t remember. It seemed
fairly obvious at the time. I knew enough
human genetics to know that there must
be a significant amount of variation in
DNA sequence. I’d been brought up in the
days of serology and biochemical genetics,
enzyme polymorphisms, and we knew that
that was sampling only a tiny proportion
of all diversity in the genome. So, if there is
diversity, then it will be agnostic with
respect to restriction sites, so if you luck
out, you’ll find a polymorphism that hits a
restriction site and that makes it assayable.
Having come up with these RFLPs, we
then got fed up with them, cause everyone
was doing it. So, we then started thinking
that surely in this enormous human
genome, there must be bits of DNA that
are more variable than these RFLPs, and
we thought intuitively that the right place
to look was tandem repeat DNA. I’ve been
brought up in the school of satellite DNAs,
which was the only class of DNA you
could purify going back to the old cesium
chloride density gradient days. The satel-
lite DNAs incidentally show a lot of
variability in copy number.
I felt intuitively that if you had local
tandem repeat sequences on a smaller
scale in the genome, they’d have potential
variation as well. The hypothesis was that
there may be bits of DNA with repeats,
maybe 10 or 20 bases long repeated 10 or
20 times, so we started all kinds of crazy
experiments trying to physically purify
these bits of DNA from the human
genome.
Then in 1980 Arlene Wyman and Ray
White described the first hypervariable
locus, so I thought WOW they do exist!
But their interpretation was one of trans-
position. Why? Because they came from a
transposable element background. So,
quite reasonably, they were thinking, OK
it’s hypervariable because we’ve got a
transposable element that is moving in and
moving out, taking DNA with it and
creating this length variation. But, I read
their interpretation of transposition and I
just felt not so sure about that. So, we then
started redoubling our efforts and still
getting nowhere at all.
Then Graeme Bell described the se-
quence of the human insulin gene and
right next door to it was a minisatellite—a
highly variable tandem repeat region. And
then Doug Higgs in the a-globin region.
Gitschier: What approach were you
using to try to find these variable
minisatellites?
Jeffreys: It was primarily physical
enrichments. These sequences might have
unusually fast reannealing kinetics, so you
could do a COT approach. Or, since these
sequences might be quite long but consist-
ed of repeats over and over again they
would tend to be resistant to restriction
enzymes, so, if you took a load of common
cutting restriction enzymes, you would
leave these things intact.
We were still getting nowhere. But
meanwhile [in a separate project], we
were doing some globin gene family
evolution work. We thought, OK there is
a missing gene in the story, and that is
myoglobin. Could we get the myoglobin
gene out and see how it fitted in to the
hemoglobin gene family as a very diverged
member of that family?
So, this is really the start of the DNA
fingerprint story, because we got the
human myoblobin gene and found a
minisatellite inside the intron.
Gitschier: How did you find that?
Jeffreys: By sequencing. It wasn’t
variable between people, but I realized I
had seen this sequence somewhere else.
So, I went back and looked at the a-globin
and the insulin minisatellites, and you
could see this sort of vague suggestion that
there might be some sort of shared
sequence in there. So, we then took that
myoglobin minisatellite and hybridized it
to a human lambda library and lo and
behold a number of clones lit up. We then
started systematically isolating those
clones, showed that they contained minis-
atellites and some of them were pretty
variable loci.
Gitschier: So, you were checking this
on a Southern blot?
Jeffreys: Southern blot and character-
izing by sequencing. And, as we were
building up the repeat sequences from the
clones coming out of the library, the
shared sequence motif, the minisatellite
core, became more and more obvious. It
was a short sequence, about 15 bases long,
embedded within the repeats of the
minisatellites. It was almost as if this was
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repetition. But, more important, it could
give you a much more effective generic
way of getting minisatellites out of the
genome, because rather than using this
crummy myoglobin probe, you take a
probe that consists of just this core
sequence repeated over and over again.
So, we took that and hybridized it to a
Southern blot, which happened to have
[DNA from] the lab technician and her
mom and dad. We got this fuzzy splodgy
mess, but the DNA fingerprint was
absolutely obvious. We got a pattern like
a fuzzy bar code. These patterns were
individual specific, and seemed to be
inherited within the family. That was a
real eureka moment, because we were
suddenly onto something completely new,
which was DNA-based identification.
Recall, the driver for this experiment
was medical genetics. You needed these
improved markers for facilitating construc-
tion of linkage maps of the human genome
and helping in linkage analysis of inherited
disease. This thing would have been useful
were it just a single location in the
genome, but the fact that there were
multiple copies of the repeat sequence in
the genome gave it a new meaning, in
terms of DNA identification.
When I talked about it in a Department
seminar, and then speculated about what
we could use this for, like catching rapists
from semen—about a third of the audi-
ence fell over laughing. It sounds bizarre
now because it’s so blindingly obvious that
you can use DNA for this, but believe me,
back in the 80s it was simply not there.
The only reason I came up with the idea
of DNA-based identification was that it
just hit you in the face!
So, within the first day, we saw
identification, we could foresee forensic
analysis if DNA survived in forensic
specimens, zygosity testing in twins, pater-
nity testing, and immigration disputes. Just
like drawing up a shopping list—if we
could get this technology improved, what
it could be applied to.
Gitschier: I clearly remember that
Nature paper [1985] involving the immigra-
tion dispute that you helped to settle, the case
where a boy was threatened with deportation
because the immigration authorities alleged
he wasn’t the biological son.
Jeffreys: That was the first DNA case
tackled anywhere in the world, and it is
still my favorite case because I was there at
the tribunal where they dropped the case
against the boy, when the mother was
told—and just the look in that mother’s
eyes! She had been fighting the case for
two years.
That was my golden moment. Without
DNA, he could have been deported.
Gitschier: That set of events must
have built up momentum for you and your
lab.
Jeffreys: Oh, it did. We hadn’t
realized how many thousands of other
people were trapped in these disputes!
So, the next thing was a complete
avalanche of letters and phone calls;
people were turning up at my home!
Gitschier: What did you do?
Jeffreys: Well, I nearly had a nervous
breakdown, but I kept going. It was an
insane two years, 1985–1987, before the
thing went commercial. We were the only
lab providing any testing at all.
Gitschier: And then there is the local
double rape/murder case in a village near
Leicester. I read ‘‘The Blooding.’’
Jeffreys: It’s a good book. It’s
accurate.
Gitschier: Ah, you’ve answered my
question. It depicted you as this chain-
smoking guy in a black jumper [sweater].
What did you think about that?
Jeffreys: Well, let me tell you a little
story.
The author was Joseph Wambaugh, an
ex-LA cop who happened to read about
the story in his dentist’s office in Hippocrates
magazine. He thought this is brilliant, and
he took the plane straight over here and
interviewed all sorts of people, myself
included. My secretary had written ‘‘in-
terview with Rambo’’ on my calendar. No
idea who he was. And I was very cautious.
He arrived, and we did not get along
terribly well, talking at cross-purposes. He
wanted to dig as deep as he possibly
could—that was his job as an author—and
my instinct was to keep stum.
It was an extraordinary case. We were
approached in 1986 by the police. They
said, we’ve got these terrible double rape/
murder cases, we have a prime suspect
who has confessed to the second murder.
We’ve heard about this DNA fingerprint-
ing and could you use this technology, not
to confirm his guilt with respect to the
second murder, we know that, but to have
a look at the first murder and see if we can
tie him in.
So, I said we’ll do this, but I explained
at the outset that we wouldn’t be using
DNA fingerprinting, but we’d use this
derived technology DNA profiling, which
we thought would be much more appro-
priate. And we said, ‘‘Don’t hold your
breath. No one has ever attempted this
before.’’
Gitschier: Tell me about profiling,
what it means, and why you used it
instead.
Jeffreys: We knew that DNA finger-
prints were too insensitive for forensic
casework. So, we simply took out the
minisatellite core probe, we went back into
our libraries of DNA and cloned out the
most variable single locus probes, each of
which gave a simple but highly variable
two-band pattern. We knew that was the
way forward.
Gitschier: OK, back to the case.
Jeffreys: The forensic samples arrived,
and I have to say that was a chilling
moment. An ordinary academic and
suddenly you’ve got murder samples in
front of you. I remember my blood
literally running cold at that point.
We put the first probe on, and the
prime suspect wasn’t a match [with the
semen sample from the second murder]!
Suddenly we were into the world of
exclusion, and how many probes do you
need for that? One. The result was so
wacky, so totally out of keeping from what
the police were expecting to see. We
thought better do another one [probe].
The results were totally astonishing, totally
overturned what the police had got fixed
in their minds about the guilt of this prime
suspect. He was released.
The police said, OK we now believe all
this DNA testing, let’s go and pan the
entire local community and see if we can
flush out the true murderer. That was all
done by Home Office forensic scientists,
who at that point had our DNA finger-
printing in place. But of those 5000
samples, only 500 were DNA fingerprint-
ed. The others were all excluded by
[biochemical] testing.
The upshot of that was that the true
perpetrator was flushed out, and the rest is
history.
Gitschier: Have you been in any other
books?
Jeffreys: I’ve certainly turned up in all
sorts of science-y books. DNA fingerprint-
ing is now part of the curriculum for kids
age 14–15 in the UK.
So, I’ve achieved that sort of rare status
of science reaching out to the public and
being understood by school kids. And
literally every 2 or 3 days I get an email,
mainly from the States, from school kids
saying, ‘‘I’ve got to do a project on a
famous scientist, so I’ve chosen you,’’ and
I love that. I always respond.
It’s great because if you think you are
doing even the tiniest bit to switch people
on to science, and this DNA stuff is
great—OJ Simpson, the Romanovs, it’s
got everybody. If you can’t hook people
into science with that story, give up.
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